Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum

References

• Guttendorf R. Meeting the demands of regulatory requirements: the significance of ADME. Bioanalysis. 2012;4(12):1395–1397. doi:10.4155/bio.12.135
   PubMed Web of Science ®Google Scholar
• Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011;13(1):99–110. doi:10.1208/s12248-011-9251-3
   PubMed Web of Science ®Google Scholar
• Lequin RM. Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA). Clin Chem. 2005;51(12):2415–2418. doi:10.1373/clinchem.2005.051532
   PubMed Web of Science ®Google Scholar
• Tu J, Bennett P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis. 2017;9(14):1107–1122. doi:10.4155/bio-2017-0084
   PubMed Web of Science ®Google Scholar
• Wang Q, Ma M. Are matrix effects the Achilles heel in the bioanalysis of biotherapeutics by ligand-binding assays? Bioanalysis. 2014;6(8):1041–1044. doi:10.4155/bio.14.62
   PubMed Web of Science ®Google Scholar
• White A. Ligand-binding assays vs chromatographic platforms for oligonucleotide quantification. Bioanalysis. 2023;15(2):53–55. doi:10.4155/bio-2023-0032
   PubMed Web of Science ®Google Scholar
• EMA/CHMP/ICH/172948/2019. ICH guideline M10 on bioanalytical method validation. European Medicines Agency [Internet]. [ cited 2023 Aug 25]. Available from: https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline
   Google Scholar
• Archer S, Brailey PM, Song M, et al. CB307: a dual targeting costimulatory Humabody VH therapeutic for treating PSMA-positive tumors. Clin Cancer Res. 2024;30(8):1595–1606. doi:10.1158/1078-0432.CCR-23-3052
   PubMed Web of Science ®Google Scholar
• Teng Y, Young JL, Edwards B, et al. Diverse human VH antibody fragments with bio-therapeutic properties from the Crescendo Mouse. New Biotechnology. 2020;55:65–76. doi:10.1016/j.nbt.2019.10.003
   PubMed Web of Science ®Google Scholar
• Nessler I, Khera E, Vance S, et al. Increased tumor penetration of single-domain antibody–drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 2020;80(6):1268–1278. doi:10.1158/0008-5472.CAN-19-2295
   PubMed Web of Science ®Google Scholar
• Mora JR, Obenauer-Kutner L, Vimal Patel V. Application of the GyrolabTM platform to ligand-binding assays: a user's perspective. Bioanalysis. 2010;2(10):1711–1715. doi:10.4155/bio.10.122
   PubMed Web of Science ®Google Scholar
• Liu R, Hoffpauir B, Chilewski SD. Accelerating regulated bioanalysis for biotherapeutics: case examples using a microfluidic ligand-binding assay platform. AAPS J. 2017;19(1):82–91. doi:10.1208/s12248-016-0006-z
   PubMed Web of Science ®Google Scholar
• Yang T-Y, Uhlinger DJ, Ayers SA, et al. Challenges in selectivity, specificity and quantitation range of ligand-binding assays: case studies using a microfluidics platform. Bioanalysis. 2014;6(8):1049–1057. doi:10.4155/bio.14.60
   PubMed Web of Science ®Google Scholar
• Prassler J, Thiel S, Pracht C, et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol. 2011;413(1):261–278. doi:10.1016/j.jmb.2011.08.012
   PubMed Web of Science ®Google Scholar
• Meng M, Wang L, Voelker T, et al. A systematic approach for developing a robust LC-MS/MS method for bioanalysis. Bioanalysis. 2013;5(1):91–115. doi:10.4155/bio.12.295
   PubMed Web of Science ®Google Scholar
• Selby C. Interference in immunoassay. Ann Clin Biochem. 1999;36(6):704–721. doi:10.1177/000456329903600603
   PubMedGoogle Scholar
• Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001;61(16):6029–6033.
   PubMed Web of Science ®Google Scholar
• Spriggs FP, Duriga N, Rathi A, et al. Resolution of matrix interference: quantitative and quasi-quantitative ligand-binding assays case studies. Bioanalysis. 2014;6(8):1093–1101. doi:10.4155/bio.14.74
   PubMed Web of Science ®Google Scholar
• DeForge LE, Loyet KM, Delarosa D, et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF and IL-17AF. J Immunol Methods. 2010;362(1–2):70–81. doi:10.1016/j.jim.2010.09.004
   PubMed Web of Science ®Google Scholar
• Chen J, Kendra K, Torri A, et al. Overcoming multimeric target interference in a bridging immunogenicity assay with soluble target receptor, target immunodepletion and mild acidic assay pH. Bioanalysis. 2020;12(15):1071–1085. doi:10.4155/bio-2020-0110
   PubMed Web of Science ®Google Scholar
• Roskos LK, Schneider A, Vainshtein I, et al. PK–PD modeling of protein drugs: implications in assay development. Bioanalysis. 2011;3(6):659–675. doi:10.4155/bio.11.28
   PubMed Web of Science ®Google Scholar
• Stevenson LF. Biomarkers, PK and immunogenicity: are we ready for integration? Bioanalysis. 2016;8(22):2287–2289. doi:10.4155/bio-2016-0226
   PubMed Web of Science ®Google Scholar
• Schuurmans Stekhoven FMAH, Gorissen MHAG, Flik G. The isoelectric point, a key to understanding a variety of biochemical problems: a minireview. Fish Physiol Biochem. 2008;34(1):1–8. doi:10.1007/s10695-007-9145-6
   PubMed Web of Science ®Google Scholar
• Engström J. Gyrolab immunoassays: miniaturization, automation and integration into a rapid workflow. Methods Mol Biol. 2023;2612:109–127. doi:10.1007/978-1-0716-2903-1_9
   PubMedGoogle Scholar
• Drake AW, Myszka DG, Klakamp SL. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem. 2004;328(1):35–43. doi:10.1016/j.ab.2003.12.025
   PubMed Web of Science ®Google Scholar
• Gyros Protein Technologies. D0012493 PIS-Gyrolab-Bioaffy-CDs.pdf. (2022) [ Internet] [ cited 2023 Aug 31]. Available from: https://www.gyrosproteintechnologies.com/hubfs/GPT/pdfs/3-Gyros/Marketing%20material/PIS/D0012493%20PIS-Gyrolab-Bioaffy-CDs.pdf
   Google Scholar
• Gyros Protein Technologies. D0026196 Gyrolab-assay-developement-guide.pdf. (2020) [ Internet] [ cited 2024 Mar 8]. Available from: https://www.gyrosproteintechnologies.com/hubfs/GPT/pdfs/3-Gyros/User%20Zone/D0026196%20Gyrolab-assay-developement-guide.pdf
   Google Scholar
• Crescendo Biologics Ltd. A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumours. [ Internet] [ cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04839991
   Google Scholar